NASDAQ:ENTA Enanta Pharmaceuticals Q4 2026 Earnings Results & Report $8.36 -0.33 (-3.74%) As of 02:05 PM Eastern This is a fair market value price provided by Massive. Learn more. Enanta Pharmaceuticals missed analyst expectations on both earnings and revenue in its Q4 2026 results, released November 18, 2026. The company reported EPS of -$0.81 versus the -$0.7240 consensus estimate, while revenue of $12.87 million fell short of the $14.62 million estimate by $1.75 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026Report DateNovember 18, 2026TimeAfter Market ClosesConference Call DateNovember 16, 2026Conference Call4:00 PM ET Enanta Pharmaceuticals EPS ResultsActual EPS-$0.81Consensus EPS -$0.7240Beat/MissMissed by -$0.0860One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEnanta Pharmaceuticals Revenue ResultsActual Revenue$12.87 millionExpected Revenue$14.62 millionBeat/MissMissed by -$1.75 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Enanta Pharmaceuticals Q4 2026 Earnings FAQ Did Enanta Pharmaceuticals beat earnings estimates for Q4 2026? Enanta Pharmaceuticals (NASDAQ:ENTA) reported earnings of -$0.81 per share for Q4 2026, missing the consensus estimate of -$0.7240. The report was announced on Wednesday, November 18, 2026. What was Enanta Pharmaceuticals' revenue for Q4 2026? Enanta Pharmaceuticals reported revenue of $12.87 million for Q4 2026, against a consensus estimate of $14.62 million. Enanta Pharmaceuticals Earnings HeadlinesEnanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2026November 17 at 3:26 AM | marketscreener.comMEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026November 16 at 5:25 PM | marketscreener.comMA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 18 at 1:00 AM | Concord Gold Capital (Ad)Enanta Pharmaceuticals Fiscal Q4 Loss Narrows, Revenue FallsNovember 16 at 5:25 PM | marketscreener.comMEnanta Pharmaceuticals (ENTA) Expected to Release Quarterly Earnings on MondayNovember 15 at 10:30 AM | americanbankingnews.comJay R. Luly to Retire as Chief Executive Officer of Enanta Pharmaceuticals, Inc. by February 1, 2027October 28, 2026 | marketscreener.comMSee More Enanta Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email. Email Address About Enanta PharmaceuticalsEnanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies. The company continues to advance a pipeline of investigational medicines, including programs targeting RSV and other viral diseases, as well as inflammatory disorders. These candidates remain subject to clinical development and regulatory review.View Enanta Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles General Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a BreakoutAmazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.